This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:mp:stages [07.18.2015] – [Stage 2: Unhealthy VDR, pathogens downregulate immune activity] sallieq | home:mp:stages [12.14.2018] – [Stage 4: Benicar and 1,25-D are fully successful at activating the VDR] sallieq | ||
---|---|---|---|
Line 9: | Line 9: | ||
- | =====Stage 1: Healthy Vitamin D Receptor (VDR), low pathogen load ===== | + | ===== Prior to immune dysfunction |
In a healthy human, the body can carefully regulate activity of the VDR, which it does by controlling the concentrations of two key forms of vitamin D: 25-D and 1,25-D. Both molecules are attracted to the Receptor and bind to it for hours at a time, after which they drop off. The essential difference between the key molecules is that when 1,25-D docks to the VDR, it turns the Receptor on; when 25-D docks to the VDR, it is turned off. When it becomes necessary to turn on the VDR, the body increases production of 1,25-D. Conversely, when an active VDR is no longer necessary, the body converts 1,25-D into 25-D. In healthy humans, this control mechanism works well. For example, in the event a pathogen is noticed, the body increases production of 1,25-D, which in turn increases activity of the VDR. | In a healthy human, the body can carefully regulate activity of the VDR, which it does by controlling the concentrations of two key forms of vitamin D: 25-D and 1,25-D. Both molecules are attracted to the Receptor and bind to it for hours at a time, after which they drop off. The essential difference between the key molecules is that when 1,25-D docks to the VDR, it turns the Receptor on; when 25-D docks to the VDR, it is turned off. When it becomes necessary to turn on the VDR, the body increases production of 1,25-D. Conversely, when an active VDR is no longer necessary, the body converts 1,25-D into 25-D. In healthy humans, this control mechanism works well. For example, in the event a pathogen is noticed, the body increases production of 1,25-D, which in turn increases activity of the VDR. | ||
- | =====Stage 2: Unhealthy VDR, pathogens downregulate | + | ===== Process of immune |
Multiple pathogens including bacteria such as " | Multiple pathogens including bacteria such as " | ||
Line 20: | Line 20: | ||
The body responds by increasing production of 1,25-D. While some 1,25-D activates the VDR, a lot does not, because the VDR is blocked by bacterial ligands and the body is never able to completely out-compete the production of bacterial substances. | The body responds by increasing production of 1,25-D. While some 1,25-D activates the VDR, a lot does not, because the VDR is blocked by bacterial ligands and the body is never able to completely out-compete the production of bacterial substances. | ||
- | The increase in 1,25-D introduces a new problem entirely. When 1,25-D reaches higher and higher levels, it begins to interfere with the activity | + | The increase in 1,25-D introduces a new problem entirely. When 1,25-D reaches higher and higher levels, it begins to interfere with important activities |
- | =====Stage 3: Benicar | + | ===== Olmesartan Medoxomil |
The Marshall Protocol (MP) is designed to interrupt the inflammatory disease process. The most important medication Marshall Protocol patients take is not the low doses of antibiotics, | The Marshall Protocol (MP) is designed to interrupt the inflammatory disease process. The most important medication Marshall Protocol patients take is not the low doses of antibiotics, | ||
Line 33: | Line 33: | ||
It should be noted that Benicar has a second action, that of an anti-inflammatory. That is why many patients report feeling //better// when taking Benicar. | It should be noted that Benicar has a second action, that of an anti-inflammatory. That is why many patients report feeling //better// when taking Benicar. | ||
- | =====Stage 4: Benicar | + | ===== Continuing treatment, Olmesartan Medoxomil |
In Stage 4, the combination of Benicar and 1,25-D is entirely successful at displacing bacterial proteins such as Capnine. Patients would be able to slow their immune response by withdrawing Benicar. Choosing to do so, however, would reduce its anti-inflammatory, | In Stage 4, the combination of Benicar and 1,25-D is entirely successful at displacing bacterial proteins such as Capnine. Patients would be able to slow their immune response by withdrawing Benicar. Choosing to do so, however, would reduce its anti-inflammatory, | ||
Line 57: | Line 57: | ||
- | {{tag> | + | {{tag>MP Simple_Explanations Starting_the_Marshall_Protocol}} |